One of the greatest challenges in cancer treatment is drug resistance. A treatment may work well at first, shrinking tumors and slowing disease progression, but over time cancer cells can adapt and learn how to survive.
This problem is especially common in advanced kidney cancer, where many patients eventually run out of effective treatment options.
Researchers from Mayo Clinic have reported encouraging early results from a clinical trial that may help address this problem. Their study tested a new experimental drug called darlifarnib alongside cabozantinib, one of the standard treatments used for advanced clear cell renal cell carcinoma, the most common form of kidney cancer in adults.
Clear cell renal cell carcinoma accounts for the majority of kidney cancer cases. While targeted therapies and immunotherapies have improved survival for many patients, the disease often becomes more difficult to control as resistance develops. This is why researchers continue to search for treatments that can overcome the cancer’s ability to adapt.
The newly reported study was designed to investigate whether darlifarnib could enhance the effects of cabozantinib. Scientists believe that darlifarnib may block important signaling pathways that cancer cells use to grow and survive. By combining it with cabozantinib, researchers hoped to prevent tumors from finding alternative routes to continue growing.
The trial was a phase 1a/b study, meaning it was among the first tests of this combination in human patients. Eighteen individuals with advanced clear cell renal cell carcinoma participated.
All had previously received cabozantinib, and many had undergone several other treatments as well. Roughly half of the participants had already received three or more previous therapies.
These patients represent a group with significant unmet medical needs because treatment options become increasingly limited after multiple therapies stop working. Finding a treatment that remains effective in this setting would be a meaningful step forward.
Among the 16 patients who could be evaluated, seven experienced measurable tumor shrinkage. This produced an overall response rate of 44%. Researchers also reported that 94% of evaluable patients achieved disease control, meaning their tumors either shrank or remained stable.
Dr. Yousef Zakharia, the study’s lead investigator and a medical oncologist at Mayo Clinic in Arizona, described the results as encouraging and emphasized the need for more effective treatments for advanced kidney cancer. He presented the findings at the 2026 International Kidney Cancer Symposium: Europe in Paris.
Researchers believe the success of the combination may stem from its ability to target multiple cancer-driving pathways at once. Cancer cells often survive treatment by activating backup systems when one pathway is blocked. The addition of darlifarnib may make it harder for tumors to use these escape mechanisms.
The findings are particularly interesting because the patients enrolled had already shown disease progression despite previous treatment. Seeing tumor shrinkage and disease stabilization in this setting suggests the combination may have the potential to overcome some forms of treatment resistance.
Still, experts caution that early-stage studies should be interpreted carefully. Small studies can sometimes produce results that are not confirmed in larger trials. Researchers must now determine whether the same benefits can be achieved consistently in a much larger patient population.
The ongoing international trial will continue evaluating the treatment combination in additional patients. Future studies will help clarify how long responses last, whether survival improves, and which patients are most likely to benefit.
If the results continue to be positive, the combination of darlifarnib and cabozantinib could eventually offer a new treatment option for patients with advanced kidney cancer who have exhausted standard therapies. For patients and families facing this disease, even small advances can make a meaningful difference.
If you care about cancer, please read studies that low-carb diet could increase overall cancer risk, and new way to increase the longevity of cancer survivors.
For more health information, please see recent studies about how to fight cancer with these anti-cancer superfoods, and results showing daily vitamin D3 supplementation may reduce cancer death risk.
Source: Mayo Clinic.
